ArticleBMC complementary medicine and therapies2020
Antiviral activity of silymarin in comparison with baicalein against EV-A71.
Article in BMC complementary medicine and therapies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- A Study on the Rationality of Baicalein in the Treatment of Osteoporosis: A Narrative Review.Current protein & peptide science · 2026Review
- Antiviral candidates for enterovirus 71: targeting viral proteome and stage-specific lifecycle interventions.Virology journal · 2025Review
- Sbmyb111 act as a transcriptional activator of flavonoid synthesis in Scutellaria baicalensis.Plant molecular biology · 2025Article
- In Vitro Antiviral Activity of a Silydianin-Rich Extract fromAntibiotics (Basel, Switzerland) · 2025Article
- The convergent evolution of influenza A virus: Implications, therapeutic strategies and what we need to know.Current research in microbial sciences · 2023Article
- Mechanistic Insights into the Pharmacological Significance of Silymarin.Molecules (Basel, Switzerland) · 2022Review
- Molecular Docking of SP40 Peptide towards Cellular Receptors for Enterovirus 71 (EV-A71).Molecules (Basel, Switzerland) · 2021Article
- Antiviral activity of silymarin and baicalein against dengue virus.Scientific reports · 2021Article
- Liver disorders in COVID-19, nutritional approaches and the use of phytochemicals.World journal of gastroenterology · 2021Review
- Functional Insights into Silymarin as an Antiviral Agent against Enterovirus A71 (EV-A71).International journal of molecular sciences · 2021Article
- Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property.Phytotherapy research : PTR · 2021Review
- Review
- Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase.Microorganisms · 2021Article
- Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.European journal of pharmacology · 2021Article
- Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19).Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe hand, foot and mouth disease (HFMD) is a febrile and exanthematous childhood disease mainly caused by Enterovirus 71 (EV-A71). In severe HFMD, virulent EV-A71 strains can cause acute flaccid paralysis and cardiopulmonary edema leading to death. Currently, no FDA approved antiviral treatment or vaccine is available for EV-A71. Flavonoids such as silymarin and baicalein are known to possess in vitro antiviral properties against viruses. In this study, the cytotoxicity and antiviral activity of silymarin, baicalein and baicalin were investigated.
methodsThe cytotoxic effects of three flavonoids towards rhabdomyosarcoma (RD) cells were first examined using cell proliferation MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. Compounds found to be non-cytotoxic in RD cells were evaluated for their in vitro antiviral properties against the EV-A71 subgenotype B4 strain 41 (5865/SIN/000009) using antiviral assays. Viral infectivity was determined by reduction of the formation of plaques in RD cells. For the measurement of RNA copy number, the real time quantitative reverse transcription PCR (qRT-PCR) was used. The most potent compound was further evaluated to determine the mode of action of inhibition by time course, virus attachment and entry assays in Vero cells.
resultsSilymarin was shown to exert direct extracellular virucidal effects against EV-A71 at 50% inhibitory concentration (IC
conclusionsSilymarin has a stronger inhibition activity against EV-A71 in comparison to baicalein. It could serve as a promising antiviral drug to treat EV-A71 infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.